fbpx
close read more
News

Servier partners with the Skolkovo Foundation to support most innovative biotech startups in Russia

19/11/2020

Servier partners with the Skolkovo Foundation to support most innovative biotech startups in Russia

On November 9th 2020, Servier and Skolkovo Foundation, based in Russia near Moscow, signed a Memorandum of Cooperation (MoU) to identify and to support the startups in the field of oncology and autoimmune diseases in the whole Russian territory.

The Skolkovo Foundation is the principal agency responsible for the Russian Skolkovo Innovation Center, the largest technopark and the most experienced biomedical innovation center in Russia. It is actively working with corporate partners as Servier in external innovation development. Its objective is to support technological entrepreneurship in Russia and the commercialization of the results of research activities.

Given its deep biotech understanding and innovative landscape knowledge, Skolkovo appeared to be the most valuable partner for Servier in Russia to get quick access to the most promising initiatives in drug development and other directions (digital medicine, cell therapy, medtech).

 

“Our partnerships philosophy is about accessing innovative new therapeutic solutions to meet patient needs. Starting a collaboration with Skolkovo Foundation, a leading innovation center in Russia, is definitely inspiring”, explains Claude Bertrand, Executive Vice-President Research & Development at Servier.

 

Becoming a key player in the fight against cancer and immune-inflammatory disease is part of Servier’s long-term strategy: “This project will make a significant contribution to the fight against cancer and immuno-inflammatory diseases, provide an additional opportunity for the local projects to enter the international market and, thereby, increase the availability of innovative therapeutic solutions for patients around the world” says Jérôme Gavet, Managing Director for Russia and EAEU at Servier.

 

 

Did you know?

Committed to fighting cancer, the Group intends to dedicate 50%

of its global R&D budget to researching cancer treatments.

 

Read the press release

Last news

News
23/06/2022
Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
News
15/06/2022
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
News
01/06/2022
Patient associations’ perception of pharmaceutical companies: Servier is making progress!